

LIST OF TABLES

Table No.	Title	Page No.
Table: 2.1	Vesicle Types with their Size and Number of Lipid Layers	39
Table: 2.2	Different Preparation Methods and the Vesicles Formed by these Methods	39
Table: 2.3	Different Liposome with their Compositions	39
Table: 2.4	Phospholipids and Cholesterol which are Used for the Preparation of Liposome and their Transition Temperature (T _c)	41
Table: 2.5	Critical parameters for some common inorganics used for supercritical technology	49
Table: 2.6	Critical conditions of commonly used supercritical solvents	52
Table: 2.7	Polymer–drug conjugates and polymeric micelles in clinical trials as anticancer agents	65
Table: 2.8	Integrins and ligands	68
Table: 2.9	Linear peptides	71
Table: 2.10	Cyclic peptide	73
Table: 3.1	Calibration for Docetaxel	144
Table: 3.2	Calibration Curve of PVA ($\lambda_{\text{max}} = 690\text{nm}$)	146
Table: 3.3	Headspace Operating Parameters	147
Table: 3.4	Preparation of diluted RGD standards	149
Table: 3.5	Calibration of RGD by BCA method	149
Table: 3.6	Calibration for estimation of phosphatidyl choline (Stewart assay)	151
Table: 3.7	Calibration for estimation of cholesterol (Zlatkis, Zak and Boyle's method)	154
Table: 4.1	Materials and Equipments	161
Table: 4.2	Variables in Box Behnken Design	164
Table: 4.3	Matrix of Box Behnken Design and Particle size response of each experimental run	165
Table: 4.4	Matrix of Box Behnken Design and yield as response of each experimental run	165

Table: 4.5	Percent Entrapment Efficiency and Particles size of DC liposomes using various lipids	167
Table: 4.6a	Variables in Box Behnken Design for formulation parameters	170
Table: 4.6b	Matrix of Box Behnken Design for optimizing formulation parameters	170
Table: 4.7	Analysis of Variance for BBD Model of Process parameters	178
Table: 4.8	Analysis of Variance for BBD Model of formulation parameters	178
Table: 4.9	Optimization of process variables	181
Table: 4.10	Variables in Box Behnken Design	182
Table: 4.11	Matrix of Box Behnken Design for optimizing formulation parameters	182
Table: 4.12	Influence of Stirring Speed	183
Table: 4.13	Variables in Box Behnken Design	184
Table: 4.14	Matrix of Box Behnken Design for optimizing formulation parameters	184
Table: 4.15	Analysis of Variance for BBD Model of formulation parameters for solvent evaporation method	194
Table: 4.16	Analysis of Variance for BBD Model of formulation parameters for nanoprecipitation method	194
Table: 4.17	Percent Entrapment Efficiency and Particles size of DC liposomes using various lipids	200
Table: 4.18	Effects of PEGylation on %EE and Particle Size	203
Table 4.19	Effect of different cryoprotectants on the particle size and redispersion of Nanoparticles	208
Table 4.20	Effect of different cryoprotectants on the particle size and redispersion of liposomes	208
Table: 4.21	Influence of amount of RGD	210
Table: 4.22	Influence of Concentration of Activating Agents	211
Table: 5.1	Materials and Equipments	220
Table 5.2	Characterization of optimized RGD conjugated and unconjugated PLGA nanoparticles of Docetaxel	224
Table: 5.3	Characterization of optimized RGD conjugated and unconjugated Liposomes of Docetaxel	225
Table: 5.4	Characterization of 6- coumarin nanoparticles	238

Table: 5.5	Characterization of 6- coumarin liposomes	238
Table: 6.1	Stability studies data of PLGA-DC-NP	246
Table: 6.2	Stability data of PLGA-DC-RGD	247
Table: 6.3	Stability data of Docetaxel liposomes	248
		260
Table: 7.1	Materials and equipments	264
Table: 7.2	Influence of concentration on the Cellular Uptake Efficiency	266
Table: 7.3	Influence of Incubation time on the Cellular Uptake Efficiency	270
Table: 7.4	Cell viability of Docetaxel and Docetaxel Nanoparticles on BT-20 cells	271
Table: 7.5	Cell viability of Docetaxel and Docetaxel Nanoparticles on MDA-MB-231 cells	272
Table: 7.6	Cell viability of Docetaxel and Docetaxel Liposomes on BT-20 cells	273
Table: 7.7	Cell viability of Docetaxel and Docetaxel Liposomes on MDA-MB-231 cells	278
Table: 7.8	IC50 values for Docetaxel and Docetaxel Nanoparticles for BT-20 cells	278
Table: 7.9	IC50 values for Docetaxel and Docetaxel Nanoparticles for MDA-MB-231 cells	278
Table: 7.10	IC50 values for Docetaxel and Docetaxel Liposomes for MDA-MB-231 cells	278
Table: 7.11	IC50 values for Docetaxel and Docetaxel Liposomes for BT-20 cells	282
Table: 7.12	Cell cycle arrest study with Docetaxel	282
Table: 7.13	Cell cycle arrest study with Docetaxel Nanoparticles (PLGA-DC)	283
Table: 7.14	Cell cycle arrest study with RGD conjugated Docetaxel Nanoparticles (PLGA-DC-RGD)	283
Table: 7.15	Cell cycle arrest study with Docetaxel Liposomes (LP-DC)	283
Table: 7.16	Cell cycle arrest study with RGD conjugated Docetaxel Liposomes (LP-DC-RGD)	289
Table: 7.17	Apoptosis Necrosis study with Docetaxel, Docetaxel Nanoparticles and RGD conjugated Docetaxel Nanoparticles	289
Table: 7.18	Apoptosis Necrosis study with Docetaxel, Docetaxel Liposomes and RGD conjugated Docetaxel Liposomes	306
Table: 8.1	Feed ratio of compounds for Docetaxel comonomer reaction	307
Table: 8.2	Composition of comonomer feed ratio	